

1. References

1. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al. Estimates the prevalence of arthritis and selected musculoskeletal disorders in the United states. *Arthritis Rheum.* 1998; 41, 778-799.
2. Gabriel SE. The epidemiology of rheumatoid arthritis. *Rheu. Dis. Clin. Norht Am* 2001; 27, 269-281.
3. Del Rineon I, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. *Arthritis Rheu.* 2001; 44, 2737-45.
4. Hilal Maradit-Kremers, Paulo J. Nicola, Cynthia S. Cynthia S. Crowson, Karala V, Ballman, and Sherine E. Gabriel. Cardiovascular death in Rheumatoid Arthritis. *Arthritis and Rheumatism* 2005; vol. 52, No. 3, 722-732.
5. Van Boekel, M. Mandema, E., Van den Hoogen, F. and Van Venrooij, W. Autoantibody systems in Rheumatoid Arthritis: specificity, sensitivity and diagnostic value. *Arthritis Res.* 2002; 4, 87-93.
6. Nienhuis, R. and Mandema, E. A new serum factor in patients with Rheumatoid Arthritis. The anti perinuclear factor. *Ann. Rheum. Dis.* 1964; 23, 302-305.
7. Schellekens, G., De Jong, B., Van den Hoogen., Van de putte, L. and Van Venrooij, W., Citrulline is an essential constituent of antigenic determinants recognized by Rheumatoid Arthritis-specific autoantibodies. *J. Clin. Invest.* 1998; 101, 273-281.
8. Visser, H., Le Cessie, S., Vos, K., Breedveld, F. and Hazes, J. How to diagnose Rheumatoid Arthritis early? A prediction model for persistent (erosive) arthritis. *Arthritis Rheum.* 2002; 46, 357-365.
9. Vossenaar, E. and Van Venrooij, W. Anti-CCP antibodies, a highly specific marker for (early) Rheumatoid Arthritis. *Clin. Applied Imm. Rev.* 2004; 4, 239-262.
10. Van Gaalen, F., Linn-Rasker, S., Van Venooij, W., de Jong, B., Breedveld, F., Verweij, C., Toes, R. and Huizinga, T. Autoantibodies to cyclic citrullinated peptides predict progression to Rheumatoid Arthritis in patients with undifferentiated arthritis. *Arthritis Rheu.* 2004; 50, 709-715.
11. Us D., Gulmez, D. and Hascelik, G. Cyclic citrullinated peptide antibodies (anti-CCP) together with some other parameters used for serologic diagnosis of rheumatoid arthritis. *Mikrobiyol But.* 2003; 37(2-3), 163-170.
12. Ates, A., Karaaslan, Y. and Aksaray, S. Predietive value of antibodies to cyclic citrullinated peptide in patients with early arthritis. *Clin. Rheumatol.* 2007; 26(4), 499-504.
13. Nielen MM, Van der Horst RA, van Schaardenburg D, van der Horst-Bruinsma IE, van de Stadt RJ, Aarden L, Dijkmans BA and Hamann D. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. *Ann Rheu Dis.* 2005; 64(8), 1199-2004.
14. Vallbracht I, Rieber J., Oppermann M, Forger F, Siebert U and Heimke K. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. *Ann. Rheum. Dis.* 2004; 63(9), 1079-1084.
15. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC and van Venrooij WJ. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptides. *Arthritis Rheum.* 2000; 43(1), 155-163.
16. Low JM, Chauhan AK, Kietz DA, Daud U, Pepmuller PH and Moore TL. Determination of anti-cyclic eitrullinated peptide antibodies in the sera of patients with juvenile idiopathic arthritis. *J. Rheumatol.* 2004; 31(9), 1829-1833.